Item 7.01 Regulation FD Disclosure. On April 6, 2026, ImmunityBio, Inc. (the “Company”) issued a press release announcing it had submitted a comprehensive response to the Warning Letter issued by the U.S. Food and Drug Administration Office of Prescription Drug Promotion on March 13, 2026 and outlining the Company’s immediate and planned corrective actions related thereto. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
IBRX Immunitybio, Inc. - 8-K
Accession
0001193125-26-1429327.019.01
Item 7.01 - Regulation FD Disclosure
148 words
Item 9.01 - Financial Statements and Exhibits
36 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 99.1* Press Release dated April 6, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Furnished herewith.